重组人红细胞生成素治疗肿瘤化疗相关性贫血388例

目的评价重组人促红细胞生成素(rhEPO)治疗肿瘤化疗相关性贫血的疗效和不良反应。方法 388例肿瘤化疗相关性贫血患者分为观察组192例和对照组196例,对照组给予一般性纠正贫血药物,观察组给予rhEPO肌肉注射。评价2组疗效和副作用。结果对照组治疗后血红蛋白(Hb)和血细胞比容(Hct)呈下降趋势,观察组治疗后Hb和Hct呈上升趋势。治疗4、6和8周后,观察组Hb和Hct均高于对照组,差别有统计学意义(P<0.05,P<0.01)。治疗6周后,观察组生活质量改善率(100.0%)明显高于对照组(21.4%),差别有统计学意义(P<0.01)。治疗后观察组的输血需求率(8.9%)明显低于对照组(25.0%),差别有统计学意义(P<0.01)。2组患者均未出现明显不良反应。结论 rhEPO治疗恶性肿瘤贫血具有一定的疗效,能提高患者的Hb和Hct,有效降低输血需求及风险,且安全性好。

Evaluation of recombinant human erythropoietin in the treatment for 388 cases with chemotherapy-related anemia

Objective To evaluate the efficacy and side effect of recombinant human erythropoietin(rhEPO) in the treatment for tumor chemotherapy-related anemia.Methods Three hundred and eighty-eight patients with chemotherapy-related anemia were divided into observation group(n = 192) and control group(n = 196),rhEPO was injected intramuscularly on patient in the observation group,while patients in the control group were treated only with conventional anti-anemia medicine.Then the efficacy and side effect of the two g...